MINT-TOPIRAMATE TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

TOPIRAMATE

Mevcut itibaren:

MINT PHARMACEUTICALS INC

ATC kodu:

N03AX11

INN (International Adı):

TOPIRAMATE

Doz:

200MG

Farmasötik formu:

TABLET

Kompozisyon:

TOPIRAMATE 200MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

MISCELLANEOUS ANTICONVULSANTS

Ürün özeti:

Active ingredient group (AIG) number: 0132938006; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2008-08-19

Ürün özellikleri

_MINT-TOPIRAMATE (topiramate) _
_Page 1 of 78_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-TOPIRAMATE
topiramate tablets, USP tablets, 25 mg, 100 mg and 200 mg, oral
Antiepileptic/Migraine Prophylaxis
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
August 19, 2008
Date of Revision:
November 28, 2023
Submission Control Number: 278199
_MINT-TOPIRAMATE (topiramate) _
_Page 2 of 78_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Ophthalmologic
09/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential, Teratogenic Risk
11/2023
7 WARNINGS AND PRECAUTIONS, Information for
Patients, Fetal Toxicity
11/2023
7.1.1 Pregnant Women
11/2023
TABLE OF CONTENTS
_Sections or subsections that are not applicable at the time of
authorization are not listed. _
RECENT MAJOR LABEL CHANGES
.........................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..................................................................................
4
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...................................